Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05463744 · ClinicalTrials.gov registry record · Phase 3

A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy

A Phase 3 study of Diabetes and Type 1 Diabetes, sponsored by Eli Lilly and Company.

Completed
Registry status
Phase 3
Development phase
692
Enrollment target
20
Study locations

NCT05463744 is a Phase 3 study of Diabetes and Type 1 Diabetes that has completed, run by Eli Lilly and Company. The registered enrollment target is 692 participants, below the 3,026-participant average among 338 other Diabetes trials with a reported enrollment target (77% lower). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05463744, a Phase 3 study of Diabetes and Type 1 Diabetes, has completed, sponsored by Eli Lilly and Company.

COMPLETED
Registry status
Phase 3
Development phase
692 participants
Enrollment target
20
Study locations

Study Summary

The main purpose of this study is to measure the safety and efficacy of insulin efsitora alfa (LY3209590) compared with insulin degludec in participants with type 1 diabetes treated with multiple daily injection therapy.

Conditions Studied

Diabetes Type 1 Diabetes

Interventions

  • DRUG Insulin Degludec
  • DRUG Insulin Efsitora Alfa

Study Locations (20)

California

  • John Muir Physician Network Research Center - Concord
  • Valley Research - Fresno
  • Catalina Research Institute, LLC - Montclair
  • Sansum Diabetes Research Institute - Santa Barbara
  • University Clinical Investigators, Inc. - Tustin

Florida

  • Northeast Research Institute (NERI) - Fleming Island
  • Jellinger and Lerman, MD PA dba The Center for Diabetes and Endocrine Care - Fort Lauderdale
  • Suncoast Clinical Research, Inc. - New Port Richey
  • Hanson Clinical Research Center - Port Charlotte

Maryland

  • MedStar Health Research Institute (MedStar Physician Based Research Network) - Hyattsville
  • Endocrine and Metabolic Consultants - Rockville

Nevada

  • Palm Research Center Tenaya - Las Vegas
  • Palm Research Center Sunset - Las Vegas

Colorado

  • University of Colorado Anschutz Medical Campus - Aurora

Georgia

  • East Coast Institute for Research at The Jones Center - Macon

Hawaii

  • East-West Medical Research Institute - Honolulu

Idaho

  • Rocky Mountain Clinical Research - Idaho Falls

Trial Details

FieldValue
Enrollment Target 692 participants
Start Date 2022-08-12
Est. Completion 2024-05-07
Phase Phase 3

Sponsor

Eli Lilly and Company

1,341 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05463744

The ClinicalTrials.gov registry entry for NCT05463744 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 692 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,026-participant average among 338 other Diabetes trials with a reported enrollment target (77% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Insulin Degludec is the first listed.

NCT05463744 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Florida, Maryland.

Frequently Asked Questions

What is clinical trial NCT05463744 about?

NCT05463744 is a clinical study titled "A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy". The main purpose of this study is to measure the safety and efficacy of insulin efsitora alfa (LY3209590) compared with insulin degludec in participants with type 1 diabetes treated with multiple daily injection therapy.

What is the current status of trial NCT05463744?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 692 participants. The study started on 2022-08-12. Estimated completion is 2024-05-07.

What conditions does trial NCT05463744 study?

This clinical trial studies the following conditions: Diabetes, Type 1 Diabetes.

What interventions are being tested in trial NCT05463744?

The interventions under investigation include: Insulin Degludec (DRUG), Insulin Efsitora Alfa (DRUG).

Who is sponsoring clinical trial NCT05463744?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05463744 being conducted?

This trial has 20 study locations across California, Colorado, Florida, Georgia, Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Diabetes

All registered trials for this condition

Type 1 Diabetes

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.